Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.33 |
| ▸ | TOP1 | P11387 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1001172 | 1.00 | LMNA (0.42) | LMNAL3MBTL1TDP1AKR1B1KDM4E | |
| SCHEMBL64935 | 1.00 | LMNA (0.42) | LMNAL3MBTL1TDP1AKR1B1KDM4E | |
| SCHEMBL368405 | 1.00 | LMNA (0.42) | LMNAL3MBTL1TDP1AKR1B1KDM4E | |
| SCHEMBL3130561 | 0.94 | LMNA (0.46) | LMNAL3MBTL1TDP1AKR1B1KDM4E | |
| SCHEMBL33584 | 0.94 | LMNA (0.46) | LMNAL3MBTL1TDP1AKR1B1KDM4E | |
| SCHEMBL1369560 | 0.94 | LMNA (0.46) | LMNAL3MBTL1TDP1AKR1B1KDM4E | |
| SCHEMBL4126076 | 0.94 | LMNA (0.46) | LMNAL3MBTL1TDP1AKR1B1KDM4E | |
| SCHEMBL3128140 | 0.94 | LMNA (0.46) | LMNAL3MBTL1TDP1AKR1B1KDM4E | |
| SCHEMBL342904 | 0.94 | LMNA (0.46) | LMNAL3MBTL1TDP1AKR1B1KDM4E | |
| SCHEMBL2316246 | 0.94 | LMNA (0.46) | LMNAL3MBTL1TDP1AKR1B1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 214 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3775904-A1 | ANTIBODY OR ANTIBODY COMBINATION AND METHOD USING SAME FOR DETECTION OF AN ANTIGEN RELATED TO MYCOBACTERIUM IN A URINE SAMPLE OF A SUBJECT | Foundation of Innovative New Diagnostics (CH) | 2021-02-17 | — | — | EP | claimed |
| CN-112005117-A | Antibodies or antibody combinations and methods of using the same to detect mycobacterial-associated antigens in a urine sample from a subject | 创新诊断基金会 | 2020-11-27 | — | — | CN | claimed |
| WO-2019186486-A1 | ANTIBODY OR ANTIBODY COMBINATION AND METHOD USING SAME FOR DETECTION OF AN ANTIGEN RELATED TO MYCOBACTERIUM IN A URINE SAMPLE OF A SUBJECT | FOUNDATION OF INNOVATIVE NEW DIAGNOSTICS (CH) | 2019-10-03 | — | — | WO | claimed |
| US-10105439-B2 | Polysaccharide fraction originating in persimmon leaf with immunostimulating activation and antitumor activation and method for manufacturing same | KOREA FOOD RESEARCH INSTITUTE (KR) | 2018-10-23 | — | — | US | claimed |
| US-9833462-B2 | Persimmon leaf-derived polysaccharide fraction having immune function-enhancing activity and method producing the same | KOREA FOOD RESEARCH INSTITUTE (KR) | 2017-12-05 | — | — | US | claimed |
| US-20160015807-A1 | POLYSACCHARIDE FRACTION ORIGINATING IN PERSIMMON LEAF WITH IMMUNOSTIMULATING ACTIVATION AND ANTITUMOR ACTIVATION AND METHOD FOR MANUFACTURING SAME | KOREA FOOD RESEARCH INSTITUTE (KR) | 2016-01-21 | — | — | US | claimed |
| US-20140302067-A1 | PERSIMMON LEAF-DERIVED POLYSACCHARIDE FRACTION HAVING IMMUNE FUNCTION-ENHANCING ACTIVITY AND METHOD PRODUCING THE SAME | KOREA FOOD RESEARCH INSTITUTE (KR) | 2014-10-09 | — | — | US | claimed |
| US-20050061313-A1 | recovery of deoxy sugars such as fucose from biomass-derived solutions, such as spent liquors obtained from pulping processes, based on use of chromatographic fractionation with specific column packing materials; product may be further purified by crystallization | DANISCO SWEETENERS OY (FI) | 2005-03-24 | — | — | US | claimed |
| EP-0125039-B1 | ENZYMATIC PRODUCTION OF PHOSPHOLIPID-SACCHARIDE DERIVATIVES | MEITO SANGYO KABUSHIKI KAISHA (JP) | 1989-02-15 | — | — | EP | claimed |
| US-4624919-A | Enzymatic production of phospholipid-saccharide derivatives | MEITO SANGYO KABUSHIKI KAISHA (JP) | 1986-11-25 | — | — | US | claimed |
| EP-0125039-A2 | Enzymatic production of phospholipid-saccharide derivatives | MEITO SANGYO KABUSHIKI KAISHA (JP) | 1984-11-14 | — | — | EP | claimed |
| US-20260125721-A1 | ACIDOPHILIC FUSARIUM OXYSPORUM STRAINS, METHODS OF THEIR PRODUCTION AND METHODS OF THEIR USE | THE FYNDER GROUP, INC. | 2026-05-07 | — | — | US | disclosed |
| US-20260035655-A1 | FILAMENTOUS FUNGAL BIOMATS, METHODS OF THEIR PRODUCTION AND METHODS OF THEIR USE | THE FYNDER GROUP INC (US) | 2026-02-05 | — | — | US | disclosed |
| EP-4622466-A1 | METHODS OF USING PROTEIN INGREDIENTS TO MAKE DOUGHS, BAKED PRODUCTS, SOUPS, BEVERAGES, AND SNACKS | Cella Farms Inc. (US) | 2025-10-01 | — | — | EP | disclosed |
| EP-4608173-A1 | CARRIER AND FILLER FOOD COMPOSITIONS WITH HIGH PROTEIN AND LOW LIPID CONTENT | Cella Farms Inc. (US) | 2025-09-03 | — | — | EP | disclosed |
| US-5153000-A | Moisture retaining | KAO CORPORATION (JP) | 1992-10-06 | — | — | US | disclosed |
| EP-0475160-A1 | Preparation for drug application in minute droplet form | Cevc, Gregor, Prof. Dr. (DE) | 1992-03-18 | — | — | EP | disclosed |
| WO-1992003122-A1 | PREPARATION FOR APPLICATION OF ACTIVE SUBSTANCES IN THE FORM OF MINIMUM-SIZED DROPLETS | CEVC GREGOR (DE) | 1992-03-05 | — | — | WO | disclosed |
| EP-0370491-A2 | Liposome comprising a novel phosphate as membrane constituent, liposome preparations and cosmetic preparations comprising said phosphate | KAO CORPORATION (JP) | 1990-05-30 | — | — | EP | disclosed |
| US-4624919-A | Enzymatic production of phospholipid-saccharide derivatives | MEITO SANGYO KABUSHIKI KAISHA (JP) | 1986-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125721-A1 | ACIDOPHILIC FUSARIUM OXYSPORUM STRAINS, METHODS OF THEIR PRODUCTION AND METHODS OF THEIR USE | TKT, SPOUT1, TALDO1 | LMNA 4845/4885L3MBTL1 1021/4885TDP1 1336/4885 |
| US-20260035655-A1 | FILAMENTOUS FUNGAL BIOMATS, METHODS OF THEIR PRODUCTION AND METHODS OF THEIR USE | ERG28, FIBP, MBOAT7 | LMNA 4567/4885L3MBTL1 2701/4885TDP1 4109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.